医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

AtriCure Announces Approval for the cryoICE™ Platform in Japan

2016年11月01日 PM07:00
このエントリーをはてなブックマークに追加


 

MASON, Ohio

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its cryoICE™ platform and CRYO2 cryoablation probe. The approval marks the first time that these products will be available in the Japanese market.

“We are pleased to have this approval in hand, and to be able to bring our cryoablation products to the Japanese market,” said Mike Carrel, President and CEO of AtriCure. “This new approval will augment our offerings in the Japanese market and offer a leading solution to cardiac surgeons and the Japanese patients for the treatment of Afib.”

The company’s distributor in Japan, Century Medical Inc. (CMI), worked closely with AtriCure to secure approval. Product will be immediately available for sale as soon as the reimbursement application is completed, which is expected in the fourth quarter.

“Japanese surgeons have been waiting a long time for this moment. We believe many patients will benefit from this technology and look forward to bringing it to market,” said Takahiko Motani, president and CEO of CMI.

About AtriCure

AtriCure, Inc. is a medical device company that provides innovative solutions designed to decrease the global Afib epidemic. AtriCure’s Isolator® Synergy™ Ablation System is the first and only surgical device approved for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip® Left Atrial Appendage Management (LAAM) exclusion device is the most widely sold device worldwide that is indicated for the occlusion of the left atrial appendage. AtriCure believes electrophysiologists and cardiothoracic surgeons are adopting its technologies for the treatment of Afib and reduction of Afib related complications. Afib affects more than 33 million people worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161101005161/en/

CONTACT

AtriCure, Inc.
Valerie Storch-Willhaus, 612-605-3311
Media
Relations
Director, Corporate Marketing and Communications
vstorch-willhaus@atricure.com
or
Andy
Wade, 513-755-4564
Investor Relations
Senior Vice President
and Chief Financial Officer
awade@AtriCure.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Dr. Reddy’s Laboratories Announces the Launch of Progesterone Capsules in the U.S. Market
  • シネクサス、世界をリードする治験実施施設ネットワークとしての能力を強化
  • Synexus提升能力成为世界领先的研究单位网络
  • Replicor披露 NAP功能性控制HBV和HDV的1年成果及有关NAP药理机制的新见解
  • ReplicorがNAPによるHBV/HDVの1年間の機能的制御の達成とNAPの薬理作用機序に関する新知見を公表